Why Your Doctor Never Mentions Sleep as a First-Line Treatment
Behavioral therapy for insomnia outperforms sleeping pills over the long run, yet thin training, 18-minute visits, and payment gaps keep it out of the exam room.
A patient with months of broken sleep leaves a primary care visit holding a prescription and a handout on “sleep hygiene.”
The visit followed a familiar script. It skipped the treatment the American College of Physicians has recommended as the starting point for chronic insomnia since 2016: cognitive behavioral therapy for insomnia, known as CBT-I.
Trending Now!!:
Doctors rarely lead with sleep because medical training devotes only a few hours to it, standard visits last about 18 minutes, and prescribing a pill is faster than arranging cognitive behavioral therapy for insomnia, the guideline-recommended first-line treatment.
Access gaps, reimbursement, and patient expectations reinforce the pattern, even though the evidence favors behavioral treatment.
The explanation is less about neglect than about structure. Training, time, payment and prescribing habits each work against behavioral sleep care and together they explain why a first-line treatment with strong evidence behind it reaches so few patients.
What the Guideline Actually Says
The American College of Physicians published its guideline in Annals of Internal Medicine on May 3, 2016. It named CBT-I the first-line treatment for adults with chronic insomnia disorder, a condition that meets diagnostic criteria in an estimated 6 to 10 percent of American adults.
CBT-I combines sleep restriction, stimulus control, cognitive work on sleep-related worry and education, and it can be delivered individually, in groups, by phone, through web modules or with self-help books. Medication enters the plan only as a shared decision after CBT-I alone has not worked, and the guideline advised limiting drugs to four to five weeks where possible.
Amir Qaseem of the college’s clinical policy department and colleagues reasoned that CBT-I is noninvasive and therefore likely to carry fewer harms, concluding that “CBT-I provides better overall value than pharmacologic treatment.”
The guideline also urged physicians to check for treatable secondary causes before continuing drugs, including depression, pain, an enlarged prostate, substance use and other sleep disorders such as sleep apnea and restless legs syndrome.
Later evidence has leaned the same way. A 2024 network meta-analysis from a team including Yuki Furukawa and Michael Perlis pooled 13 trials and 823 participants and found that CBT-I produced better long-term remission than pharmacotherapy as an initial treatment.
Against an average 28 percent long-term remission rate in the drug-first arms, CBT-I reached an estimated 41 percent. Adding medication to CBT-I showed no clear advantage, and CBT-I patients dropped out less often than patients on drugs.
The Four Gates Between Evidence and the Exam Room
Four structural gates account for most of the distance between the guideline and the average appointment. Each operates independently, which is why fixing one rarely changes the outcome.
Gate One: Training
Sleep barely registers in the medical curriculum. A national survey of 126 US medical schools found an average of less than two hours of teaching on sleep and sleep disorders, with 37 schools reporting no structured instruction at all.
Only 8 percent of students were trained in sleep laboratory procedures, and 11 percent had taken part in evaluating a patient with a sleep disorder. A follow-up survey in 1998 recorded 2.1 hours.
A 2011 study of 106 medical schools in 10 countries found under 2.5 hours, and a 2020 survey of UK schools reported a median of 1.5 hours, a gain on the 15 minutes recorded two decades earlier but hardly a transformation.
The consequence shows up in the consulting room. Commentary in the AMA Journal of Ethics observed that few physicians outside sleep medicine ask about sleep when taking a history.
A 2018 review in the Journal of General Internal Medicine added that primary care providers often fail to screen and refer because of limited knowledge, treatment beliefs and low motivation to assess insomnia, while shortages of behavioral sleep medicine providers block referrals even when intent exists.
Gate Two: Time
The average primary care exam lasts about 18 minutes, according to an analysis of electronic health record timestamps from more than 21 million visits in 2017.
This window must cover medication reconciliation, chronic disease management, the complaint that prompted the booking and documentation. Explaining CBT-I fits poorly inside it, and delivering it does not fit at all. A prescription is the one sleep intervention that does.
A JAMA Health Forum study of more than 8 million visits to 8,091 primary care physicians found that shorter visits were associated with more potentially inappropriate prescribing, with older patients showing the same pattern. The finding concerns prescribing broadly, but it describes the pressure that makes a quick script the path of least resistance.
Gate Three: Access and Payment
CBT-I is a skilled therapy delivered by a thin workforce, and the shortage is global. Flinders University researchers report that only 1 percent of Australians with insomnia access it. Research fellow Alexander Sweetman said sleeping pills remain the “mainstay management option for insomnia” despite evidence that behavioral treatment works better over the long term.
In the UK, geriatricians writing for the British Geriatrics Society describe face-to-face CBT-I as largely unavailable because of a shortage of trained therapists, and note that NHS England has yet to make NICE-recommended digital CBT-I available nationwide. A 2019 letter in the British Journal of General Practice put NHS prescriptions for sleeping pills at roughly 12 million a year.
Claims data point to the same way in the United States, with a caveat. One benefits consultancy’s three-year analysis found that 91.5 percent of members treated for insomnia received a prescription only, 5.4 percent received a prescription plus CBT-I, and 3.1 percent received CBT-I alone, and about two-thirds were first seen by a primary care physician.
The figures come from one consultant’s book of business, not a national registry, but the direction matches the clinical literature.
Digital delivery is the most credible fix. The FDA cleared SleepioRx, a prescription digital CBT-I program, in August 2024, joining Somryst, a nine-week program first developed by Pear Therapeutics, which later went bankrupt, with Nox Health acquiring the asset.
Medicare finalized three digital mental health treatment billing codes effective January 1, 2025, giving practices a way to be paid for ordering such programs. Reimbursement elsewhere remains uneven, and traditional Medicare patients still owe 20 percent coinsurance on covered services.
Gate Four: The Prescription Reflex
Pills fit the rhythm of a visit and the expectations of many patients. CBT-I asks for the opposite: a sleep diary, a fixed wake time and a deliberately limited window in bed during the first weeks, which can worsen daytime sleepiness before sleep consolidates. Patients accustomed to a pill as the end of a visit can read a behavioral program as being sent away with homework.
Medication is not the villain. The guideline allows it after CBT-I alone falls short, and some patients need it. The cost of using it first and for long is what the safety record documents. On April 30, 2019, the FDA required boxed warnings on zolpidem, eszopiclone and zaleplon after reviewing 66 cases of “complex sleep behaviors” such as sleepwalking and sleep driving, 20 of them fatal.
The agency stressed that the events are rare but can occur after a single dose, including at the lowest recommended dose.
Misconceptions That Keep Sleep Off the Treatment List
Sleep hygiene is not the first-line treatment. Advice on caffeine, screens and bedroom temperature is sensible, yet clinicians writing for the British Geriatrics Society note it has not proven particularly effective for insomnia on its own. A handout can stand in for CBT-I without delivering it, and patients who try it and fail may conclude that behavioral approaches do not work.
The claim that doctors never mention sleep is also overstated. The American Heart Association added sleep duration to Life’s Essential 8 in 2022, alongside diet, activity, nicotine exposure, weight, blood lipids, blood sugar and blood pressure, and cardiovascular guidance now treats sleep as a modifiable risk factor.
A physician who skips behavioral sleep treatment may still be screening for sleep apnea, a different problem that needs a different test. The gap lies in treatment pathways more than in awareness.
Insomnia is not merely a symptom to be treated by fixing something else first. CBT-I targets the habits and thoughts that sustain sleeplessness regardless of what started it, which is why a search for secondary causes and behavioral treatment can proceed together.
Not every patient is a candidate for every component, either. Sleep restriction is typically supervised more closely in people with conditions such as bipolar disorder or seizure disorders, and drowsy driving is a real concern during the early weeks, which is one reason referral to a behavioral sleep medicine specialist matters.
How to Raise Sleep Treatment With a Doctor
Patients can shift the order of the visit. A two-week sleep diary gives a physician usable data in a short appointment, and a few specific requests move the conversation from prescribing to planning.
- Ask whether the pattern meets the threshold for chronic insomnia, generally trouble sleeping at least three nights a week for three months.
- Request a check for sleep apnea, restless legs syndrome, depression, pain or a current medication as contributing causes, the same secondary causes the ACP guideline lists.
- Name CBT-I directly, and ask about referral to a behavioral sleep medicine specialist, group or telehealth programs, or an FDA-cleared digital program.
- Check coverage before committing, since digital program billing codes have existed for Medicare since January 2025 while private plans vary.
- Settle the exit plan for any prescription: how long it is meant to last, how it will be stopped, and whether the drug carries the FDA boxed warning.
The system, not the individual physician, steers sleep out of the room. Until behavioral sleep care is taught earlier, scheduled into longer visits and paid for in ways that make referral easy, patients with insomnia will keep leaving appointments with a prescription first. A patient who arrives knowing the guideline can reverse the order.
What People Ask
